Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by:
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00393354
First received: October 26, 2006
Last updated: May 20, 2013
Last verified: May 2013

October 26, 2006
May 20, 2013
April 2000
November 2000   (final data collection date for primary outcome measure)
Low back pain intensity scale (0-100 mm VAS) over 4 weeks compared to placebo
Same as current
Complete list of historical versions of study NCT00393354 on ClinicalTrials.gov Archive Site
Low back pain intensity scale (0-100 mm VAS) over 12 weeks compared to placebo
Same as current
Not Provided
Not Provided
 
Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)(COMPLETED)
A Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Trial to Assess the Efficacy and Safety of MK0663 in Patients With Chronic Low Back Pain

Study the effect of etoricoxib 60 mg and 90 mg compared to placebo to treat chronic low back pain.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Recurrent Low Back Pain
  • Drug: MK0663, Etoricoxib / Duration of Treatment : 12 Weeks
  • Drug: Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
300
Not Provided
November 2000   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Low back pain for previous 3 months and majority of days in last month
  • Regular use of acetaminophen or NSAID to treat low back pain in past month
  • Judged to be in otherwise good health

Exclusion Criteria:

  • Low back pain that is due to secondary causes
  • Radicular/myelopathic pain
  • Surgery for low back pain within the past 6 months
  • Active lawsuit or claim pertaining to their low back pain
  • Disease that may confound the results of the study or pose risk to the patients
  • Corticosteroid use in past month
  • Previous participation in MK0663 study
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00393354
2006_548, MK0663-041
Not Provided
Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP